{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:00:46Z","timestamp":1708534846947},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This update begins with muscle manifestations of coronavirus 2019. They may include myalgias and elevations in serum creatine kinase. It is unknown whether there is direct muscle invasion and how often the critically ill have muscle sequelae. Regarding autoimmune myopathies, a retrospective study of statin-induced necrotizing myopathy is covered. A relatively large proportion of patients had normal strength at presentation. Examples of dermatomyositis associated with immune checkpoint inhibitors are provided including one with cytokine storm. A report of juvenile dermatomyositis with severe abdominal complications is noteworthy. Two articles address unusual associations with inclusion body myositis, namely, spinocerebellar ataxias and granuloma myositis. In the category of muscular dystrophies, a relatively large single center study of the outcome of scapulothoracic arthrodesis for facioscapulohumeral muscular dystrophy is discussed and a article on anoctaminopathies with pauci- or asymptomatic hyperCKemia.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000329","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T22:19:43Z","timestamp":1605651583000},"page":"77-83","source":"Crossref","is-referenced-by-count":2,"title":["What is in the Myopathy Literature?"],"prefix":"10.1097","volume":"22","author":[{"given":"David","family":"Lacomis","sequence":"first","affiliation":[{"name":"Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/ane.13266","article-title":"Neurological manifestations of covid-19: a systematic review and current update","volume":"142","author":"Whittaker","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.25807","article-title":"COVID-19: a global threat to the nervous system","volume":"88","author":"Koralnik","year":"2020","journal-title":"Ann Neurol."},{"key":"R3-20230902","first-page":"1","article-title":"Neurological involvement of coronavirus disease 2019: a systematic review","volume":"19","author":"Ghannam","year":"2020","journal-title":"J Neurol."},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of covid-19","volume":"19","author":"Ellul","year":"2020","journal-title":"Lancet Neurol."},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/WNL.0000000000009566","article-title":"COVID-19 and neuromuscular disorders","volume":"94","author":"Guidon","year":"2020","journal-title":"Neurology"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1212\/NXI.0000000000000781","article-title":"Guillain-Barre syndrome: the first documented COVID-19 triggered autoimmune neurologic disease. More to come with myositis is the offing","volume":"7","author":"Dalakas","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med."},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3201\/eid2607.200445","article-title":"Rhabdomyolysis as potential late complication associated with COVID-19","volume":"26","author":"Jin","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"R10-20230902","first-page":"e7561","article-title":"Rhabdomyolysis as a presentation of 2019 novel coronavirus disease","volume":"12","author":"Suwanwongse","year":"2020","journal-title":"Cureus"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med."},{"key":"R12-20230902","first-page":"1","article-title":"Significant reduction of physical activity in patients with neuromuscular disease during covid-19 pandemic: the long-term consequences of quarantine","volume":"13","author":"Stefano","year":"2020","journal-title":"J Neurol."},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol."},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature","volume":"30","author":"Kosche","year":"2020","journal-title":"Melanoma Res."},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"e19741","DOI":"10.1097\/MD.0000000000019741","article-title":"A case report of fulminant cytokine release syndrome complicated by dermatomyositis after combination therapy with immune checkpoint inhibitors","volume":"99","author":"Ohira","year":"2020","journal-title":"Medicine"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MPG.0000000000002575","article-title":"Severe abdominal manifestations in juvenile dermatomyositis","volume":"70","author":"Besnard","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jnnp-2020-323270","article-title":"Inclusion body myositis in patients with spinocerebellar ataxia types 3 and 6","volume":"91","author":"Rietveld","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"e910","DOI":"10.1212\/WNL.0000000000008863","article-title":"Granulomatosis- associated myositis high prevalence of sporadic inclusion body myositis","volume":"94","author":"Dieudonne","year":"2020","journal-title":"Neurology"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2106\/JBJS.19.00571","article-title":"Functional outcomes and complications following scapulothoracic arthrodesis in patients with facioscapulohumeral dystrophy","volume":"102","author":"Eren","year":"2020","journal-title":"J Bone Joint Surg Am."},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00415-020-09872-7","article-title":"Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum","volume":"267","author":"Panades-de Oliveira","year":"2020","journal-title":"J Neurol."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T05:16:17Z","timestamp":1693631777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000329","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}